

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Glow LifeTech Corp. (the "Issuer").

Trading Symbol: GLOW

Number of Outstanding Listed Securities: 56,278,546

Date: April 16, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Glow LifeTech Corp. commenced trading on the CSE on March 15, 2021 under the symbol "GLOW" after completing a business combination and listing as described below.

Glow LifeTech is a Canadian-based biotechnology company focused on producing nutraceutical and cannabinoid-based products with dramatically enhanced bioavailability, absorption and effectiveness. Glow LifeTech has rights to the ground breaking, plant-based MyCell Technology® delivery system, which transforms poorly absorbed natural compounds into enhanced water-compatible concentrates, unlocking the full healing potential of natural active compounds.

2. Provide a general overview and discussion of the activities of management.

Management continued to be involved in the development of its business as more specifically detailed in 1 above.

In addition, the Company completed its previously announced business combination (the "Transaction") with Glow LifeTech Ltd. ("Glow Ltd."), whereby the Company acquired all of the issued and outstanding shares of Glow Ltd. pursuant to a three-cornered amalgamation in accordance with Section 174 of the Business Corporations Act (Ontario). Pursuant to the Business Combination Agreement, the Company issued an aggregate of 47,334,379 common shares (the "Consideration Shares") of the Company to the former Glow Ltd. shareholders (the "Glow Shareholders"), such that upon completion of the Transaction the former Glow Shareholders hold approximately 84% of the total number of the issued and outstanding common shares in the capital of the Company. All outstanding unexercised warrants in the capital of Glow Ltd. (the "Glow Warrants") to acquire common shares in the capital of Glow will be cancelled. In consideration for such disposition, the holders of the Glow Warrants received replacement warrants (the "Replacement Warrants"), to acquire one post-consolidation common share in the capital of the Company (each, a "Common Shares"), such Replacement Warrants bearing the same terms and conditions as the Glow Warrants.

The board of directors of the Company was reconstituted in conjunction with the completion of the Transaction such that it now consists of five (5) directors: Clark Kent, Greg Falck, Medhanie Tekeste, Chris Irwin and Roberto Carducci. In addition, management of the Company was reconstituted such that it now consists of Clark Kent, President and CEO, Chris Hopkins as CFO, Roberto Carducci as the Chief Commercial Officer, and James Van Staveren as Corporate Secretary.

Prior to the completion of the Transaction, the Company changed its name from "Ateba Resources Inc." to its current name, "Glow LifeTech Corp." in accordance with the provisions of the Business Corporations Act (Ontario). Also prior to the completion of the Transaction, the Company consolidated its common shares on the basis of one and one-half (1.5) pre-consolidation common shares for one (1) post-consolidation common share.

- 3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

Management continued to be involved in the development of its business and product launches as more specifically detailed in 1 above.

- 4. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**

None in the month of March 2021.

- 5. Report on any labour disputes and resolutions of those disputes if applicable.**

None in the month of March 2021.

- 6. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

None in the month of March 2021.

- 7. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

None in the month of March 2021.

- 8. Provide details of any securities issued and options or warrants granted.**

In connection with the Transaction, Glow Ltd. completed a non-brokered private placement financing of 17,138,432 units of Glow Ltd. (the "Units") at a price of \$0.30 per Unit for gross proceeds of \$5,141,529.60. Each Unit is comprised of one common share in the capital of Glow Ltd. (each, a "Unit Share") and one-half of one whole common share purchase warrant (each whole warrant, a "Warrant") exercisable at a price of \$0.40 per common share (each a "Warrant Share") for a period of two years from the date of issuance.

Prior to the completion of the Transaction, the Company settled an aggregate of \$175,000 of indebtedness owed to an arm's length creditor through the issuance of 8,750,000 pre-consolidation common shares of the Company at a price of \$0.02 per common share (the "Debt Settlement"). All Common Shares issued in connection with the Debt Settlement are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.

The Company granted 8,800,671 warrants and 10,800,000 options in the month of March.

- 9. Provide details of any loans to or by Related Persons.**

None in the month of March 2021.

10. Provide details of any changes in directors, officers or committee members.

W. Clark Kent to Chief Executive Officer & Director
Tom Glawdel to PhD, Chief Operations Officer
Rob Carducci to Chief Commercial Officer
Chris Hopkins to Chief Financial Officer

Medhanie Tekeste to Independent Director
Chris Irwin to Independent Director

11. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

On March 12, 2020, the World Health Organization (“WHO”) declared a global pandemic as a result of the COVID-19 virus. The impacts on global commerce are expected to be far reaching and, at this point, unknown. The global lock-down impacts have negatively impacted the economy as a whole and capital markets in Canada. The effects on the Company's operations have been minor to date but management continues to monitor and contingency plan.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 16, 2021.

Clark Kent

**Name of Director or Senior
Officer**

“W. Clark Kent”

Signature

President & Chief Executive
Officer

Official Capacity

Issuer Details Name of Issuer Relay Medical Corp.	For Month End March 31, 2021	Date of Report YY/MM/D 2021/04/16
Issuer Address 65 International Blvd. Suite 206		
City/Province/Postal Code Toronto, ON M9W 6L9	Issuer Fax No. 1-844-247-6633	Issuer Telephone No. 647-872-9982
Contact Name W. Clark Kent	Contact Position President	Contact Telephone No. 647-872-9982
Contact Email Address ckent@glowlifetech.com	Web Site Address https://www.glowlifetech.com/	